Tashiro T, Nagai H, Yamasaki H, Kuroda Y, Goto Y, Goto J, Nasu M
Gan To Kagaku Ryoho. 1986 Jul;13(7):2383-8.
Serum levels of neuron-specific enolase (NSE), squamous cell carcinoma-related antigen (SCC antigen) and carcinoembryonic antigen (CEA) were measured in 53 untreated patients with carcinoma of the lung. The positive rates of serum NSE were 17.0% in all patients with lung cancer, 53.8% in small cell carcinoma, 6.7% in adenocarcinoma, 5.0% in squamous cell carcinoma and 0% in large cell carcinoma; 0% in stage I, 14.3% in stage III and 26.7% in stage IV. The positive rates of serum SCC antigen were 45.3% overall, 70.0% in squamous cell carcinoma, 40.0% in adenocarcinoma, 23.1% in small cell carcinoma and 0% in large cell carcinoma; 42.9% in stage I, 57.1% in stage III and 46.7% in stage IV. In comparison with serum CEA, serum NSE and SCC antigen were much more specific in small cell carcinoma and squamous cell carcinoma, respectively. Moreover, serum levels of NSE and SCC antigen changed in parallel with the clinical course during the treatments. In conclusion, serum NSE and SCC antigen were considered to be very useful markers of lung cancer, especially of small cell carcinoma and squamous cell carcinoma, respectively.
对53例未经治疗的肺癌患者测定了血清神经元特异性烯醇化酶（NSE）、鳞状细胞癌相关抗原（SCC抗原）和癌胚抗原（CEA）水平。血清NSE在所有肺癌患者中的阳性率为17.0%，在小细胞癌中为53.8%，在腺癌中为6.7%，在鳞状细胞癌中为5.0%，在大细胞癌中为0%；在Ⅰ期为0%，在Ⅲ期为14.3%，在Ⅳ期为26.7%。血清SCC抗原的总体阳性率为45.3%，在鳞状细胞癌中为70.0%，在腺癌中为40.0%，在小细胞癌中为23.1%，在大细胞癌中为0%；在Ⅰ期为42.9%，在Ⅲ期为57.1%，在Ⅳ期为46.7%。与血清CEA相比，血清NSE和SCC抗原分别在小细胞癌和鳞状细胞癌中具有更高的特异性。此外，在治疗过程中，血清NSE和SCC抗原水平随临床病程平行变化。总之，血清NSE和SCC抗原被认为是肺癌尤其是小细胞癌和鳞状细胞癌非常有用的标志物。
